PMID- 32610077
OWN - NLM
STAT- MEDLINE
DCOM- 20210413
LR  - 20240210
IS  - 1097-4180 (Electronic)
IS  - 1074-7613 (Print)
IS  - 1074-7613 (Linking)
VI  - 53
IP  - 2
DP  - 2020 Aug 18
TI  - Transcriptional and Functional Analysis of CD1c(+) Human Dendritic Cells 
      Identifies a CD163(+) Subset Priming CD8(+)CD103(+) T Cells.
PG  - 335-352.e8
LID - S1074-7613(20)30232-6 [pii]
LID - 10.1016/j.immuni.2020.06.002 [doi]
AB  - Dendritic cells (DCs) are antigen-presenting cells controlling T cell activation. 
      In humans, the diversity, ontogeny, and functional capabilities of DC subsets are 
      not fully understood. Here, we identified circulating CD88(-)CD1c(+)CD163(+) DCs 
      (called DC3s) as immediate precursors of inflammatory 
      CD88(-)CD14(+)CD1c(+)CD163(+)FcepsilonRI(+) DCs. DC3s develop via a specific pathway 
      activated by GM-CSF, independent of cDC-restricted (CDP) and monocyte-restricted 
      (cMoP) progenitors. Like classical DCs but unlike monocytes, DC3s drove 
      activation of naive T cells. In vitro, DC3s displayed a distinctive ability to 
      prime CD8(+) T cells expressing a tissue homing signature and the epithelial 
      homing alpha-E integrin (CD103) through transforming growth factor beta (TGF-beta) 
      signaling. In vivo, DC3s infiltrated luminal breast cancer primary tumors, and 
      DC3 infiltration correlated positively with CD8(+)CD103(+)CD69(+) tissue-resident 
      memory T cells. Together, these findings define DC3s as a lineage of inflammatory 
      DCs endowed with a strong potential to regulate tumor immunity.
CI  - Copyright (c) 2020 The Author(s). Published by Elsevier Inc. All rights reserved.
FAU - Bourdely, Pierre
AU  - Bourdely P
AD  - Centre for Inflammation Biology and Cancer Immunology, The Peter Gorer Department 
      of Immunobiology, School of Immunology & Microbial Sciences, King's College 
      London, London, UK; Cancer Research UK King's Health Partner Cancer Centre, 
      King's College London, London, UK.
FAU - Anselmi, Giorgio
AU  - Anselmi G
AD  - Centre for Inflammation Biology and Cancer Immunology, The Peter Gorer Department 
      of Immunobiology, School of Immunology & Microbial Sciences, King's College 
      London, London, UK; Cancer Research UK King's Health Partner Cancer Centre, 
      King's College London, London, UK.
FAU - Vaivode, Kristine
AU  - Vaivode K
AD  - Centre for Inflammation Biology and Cancer Immunology, The Peter Gorer Department 
      of Immunobiology, School of Immunology & Microbial Sciences, King's College 
      London, London, UK; Cancer Research UK King's Health Partner Cancer Centre, 
      King's College London, London, UK.
FAU - Ramos, Rodrigo Nalio
AU  - Ramos RN
AD  - PSL Research University, Institut Curie Research Center, Translational 
      Immunotherapy Team, INSERM U932, Paris, France.
FAU - Missolo-Koussou, Yoann
AU  - Missolo-Koussou Y
AD  - PSL Research University, Institut Curie Research Center, Translational 
      Immunotherapy Team, INSERM U932, Paris, France.
FAU - Hidalgo, Sofia
AU  - Hidalgo S
AD  - PSL Research University, Institut Curie Research Center, Translational 
      Immunotherapy Team, INSERM U932, Paris, France; Laboratory of Immuno-oncology, 
      Fundacion Ciencia & Vida, Santiago, Chile.
FAU - Tosselo, Jimena
AU  - Tosselo J
AD  - PSL Research University, Institut Curie Research Center, Translational 
      Immunotherapy Team, INSERM U932, Paris, France.
FAU - Nunez, Nicolas
AU  - Nunez N
AD  - PSL Research University, Institut Curie Research Center, Translational 
      Immunotherapy Team, INSERM U932, Paris, France.
FAU - Richer, Wilfrid
AU  - Richer W
AD  - PSL Research University, Institut Curie Research Center, Translational 
      Immunotherapy Team, INSERM U932, Paris, France.
FAU - Vincent-Salomon, Anne
AU  - Vincent-Salomon A
AD  - PSL Research University, Institut Curie, Department of Biopathology, Paris, 
      France.
FAU - Saxena, Alka
AU  - Saxena A
AD  - National Institute of Health Research Biomedical Research Centre at Guy's and St 
      Thomas' Hospital and King's College London, London, UK.
FAU - Wood, Kristie
AU  - Wood K
AD  - National Institute of Health Research Biomedical Research Centre at Guy's and St 
      Thomas' Hospital and King's College London, London, UK.
FAU - Lladser, Alvaro
AU  - Lladser A
AD  - Laboratory of Immuno-oncology, Fundacion Ciencia & Vida, Santiago, Chile; 
      Facultad de Medicina y Ciencia, Universidad San Sebastian, Santiago, Chile.
FAU - Piaggio, Eliane
AU  - Piaggio E
AD  - PSL Research University, Institut Curie Research Center, Translational 
      Immunotherapy Team, INSERM U932, Paris, France.
FAU - Helft, Julie
AU  - Helft J
AD  - PSL Research University, Institut Curie Research Center, Translational 
      Immunotherapy Team, INSERM U932, Paris, France.
FAU - Guermonprez, Pierre
AU  - Guermonprez P
AD  - Centre for Inflammation Biology and Cancer Immunology, The Peter Gorer Department 
      of Immunobiology, School of Immunology & Microbial Sciences, King's College 
      London, London, UK; Cancer Research UK King's Health Partner Cancer Centre, 
      King's College London, London, UK; Universite de Paris, Centre for Inflammation 
      Research, CNRS ERL8252, INSERM1149 Paris, France. Electronic address: 
      pierre.guermonprez@kcl.ac.uk.
LA  - eng
GR  - 22369/CRUK_/Cancer Research UK/United Kingdom
GR  - NC/K001868/1/NC3RS_/National Centre for the Replacement, Refinement and Reduction 
      of Animals in Research/United Kingdom
GR  - DH_/Department of Health/United Kingdom
GR  - BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200630
PL  - United States
TA  - Immunity
JT  - Immunity
JID - 9432918
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, CD1)
RN  - 0 (Antigens, Differentiation, Myelomonocytic)
RN  - 0 (CD163 antigen)
RN  - 0 (CD1C protein, human)
RN  - 0 (CD8 Antigens)
RN  - 0 (CSF2 protein, human)
RN  - 0 (Glycoproteins)
RN  - 0 (Integrin alpha Chains)
RN  - 0 (Receptors, Cell Surface)
RN  - 0 (TGFB1 protein, human)
RN  - 0 (Transforming Growth Factor beta1)
RN  - 0 (alpha E integrins)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
RN  - EC 2.7.10.1 (FLT3 protein, human)
RN  - EC 2.7.10.1 (fms-Like Tyrosine Kinase 3)
SB  - IM
CIN - Immunity. 2020 Aug 18;53(2):233-235. PMID: 32814019
MH  - Animals
MH  - Antigens, CD/*metabolism
MH  - Antigens, CD1/*metabolism
MH  - Antigens, Differentiation, Myelomonocytic/*metabolism
MH  - Breast Neoplasms/*immunology
MH  - CD8 Antigens/metabolism
MH  - CD8-Positive T-Lymphocytes/*cytology/immunology
MH  - Cell Differentiation/immunology
MH  - Cell Line, Tumor
MH  - Dendritic Cells/*immunology
MH  - Glycoproteins/*metabolism
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/metabolism
MH  - Humans
MH  - Integrin alpha Chains/*metabolism
MH  - Lymphocyte Activation/immunology
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Receptors, Cell Surface/*metabolism
MH  - Transforming Growth Factor beta1/metabolism
MH  - fms-Like Tyrosine Kinase 3/metabolism
PMC - PMC7445430
OTO - NOTNLM
OT  - DC progenitors
OT  - DC3s
OT  - T(RM)
OT  - cDC2s
OT  - conventional DCs
OT  - inflammatory DCs
OT  - monocytes
OT  - mononuclear phagocytes
COIS- Declaration of Interests The authors declare no competing interests.
EDAT- 2020/07/02 06:00
MHDA- 2021/04/14 06:00
PMCR- 2020/08/18
CRDT- 2020/07/02 06:00
PHST- 2019/05/18 00:00 [received]
PHST- 2020/04/15 00:00 [revised]
PHST- 2020/05/29 00:00 [accepted]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/04/14 06:00 [medline]
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/08/18 00:00 [pmc-release]
AID - S1074-7613(20)30232-6 [pii]
AID - 10.1016/j.immuni.2020.06.002 [doi]
PST - ppublish
SO  - Immunity. 2020 Aug 18;53(2):335-352.e8. doi: 10.1016/j.immuni.2020.06.002. Epub 
      2020 Jun 30.